(Q37879608)

24 August 2017

1 reference

title

Recombinant human angiotensin-converting enzyme 2 as a new renin-angiotensin system peptidase for heart failure therapy (English)

1 reference

24 August 2017

0 references

2

Josef M Penninger

1 reference

24 August 2017

Gavin Y Oudit

1

1 reference

24 August 2017

publication date

1 September 2011

1 reference

Current heart failure reports

24 August 2017

published in

1 reference

24 August 2017

volume

8

1 reference

24 August 2017

issue

3

1 reference

24 August 2017

page(s)

176-183

1 reference

Drugs targeting the renin-angiotensin-aldosterone system

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11897-011-0063-7

A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-011-0063-7

A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-011-0063-7

Angiotensin-converting enzyme 2 is an essential regulator of heart function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-011-0063-7

Angiotensin II-mediated oxidative stress and inflammation mediate the age-dependent cardiomyopathy in ACE2 null mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-011-0063-7

Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-011-0063-7

Angiotensin converting enzyme-2 confers endothelial protection and attenuates atherosclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-011-0063-7

Transgenic angiotensin-converting enzyme 2 overexpression in vessels of SHRSP rats reduces blood pressure and improves endothelial function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-011-0063-7

Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2: prevention of angiotensin II-dependent hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-011-0063-7

Loss of angiotensin-converting enzyme-2 leads to the late development of angiotensin II-dependent glomerulosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-011-0063-7

Human recombinant ACE2 reduces the progression of diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-011-0063-7

Prevention of angiotensin II-mediated renal oxidative stress, inflammation, and fibrosis by angiotensin-converting enzyme 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-011-0063-7

Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-011-0063-7

Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-011-0063-7

Angiotensin(1-7) Blunts Hypertensive Cardiac Remodeling by a Direct Effect on the Heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-011-0063-7

Distinct roles for angiotensin-converting enzyme 2 and carboxypeptidase A in the processing of angiotensins within the murine heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-011-0063-7

Loss of angiotensin-converting enzyme 2 accelerates maladaptive left ventricular remodeling in response to myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-011-0063-7

Angiotensin-(1-7) and its receptor as a potential targets for new cardiovascular drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-011-0063-7

Characterization of apelin, the ligand for the APJ receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-011-0063-7

International Union of Basic and Clinical Pharmacology. LXXIV. Apelin receptor nomenclature, distribution, pharmacology, and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-011-0063-7

Outcome of heart failure with preserved ejection fraction in a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-011-0063-7

Trends in prevalence and outcome of heart failure with preserved ejection fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-011-0063-7

New concepts in diastolic dysfunction and diastolic heart failure: Part II: causal mechanisms and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-011-0063-7

Angiotensin-(1-7) binds to specific receptors on cardiac fibroblasts to initiate antifibrotic and antitrophic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-011-0063-7

Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-011-0063-7

ACE2 overexpression inhibits hypoxia-induced collagen production by cardiac fibroblasts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-011-0063-7

Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-011-0063-7

Altered blood pressure responses and normal cardiac phenotype in ACE2-null mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-011-0063-7

ACE2 gene expression is up-regulated in the human failing heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-011-0063-7

Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-011-0063-7

Myocardial infarction increases ACE2 expression in rat and humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-011-0063-7

Deletion of angiotensin-converting enzyme 2 accelerates pressure overload-induced cardiac dysfunction by increasing local angiotensin II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-011-0063-7

Association of angiotensin-converting enzyme 2 (ACE2) gene polymorphisms with parameters of left ventricular hypertrophy in men

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-011-0063-7

Association of angiotensin-converting enzyme 2 gene A/G polymorphism and elevated blood pressure in Chinese patients with metabolic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-011-0063-7

Soluble angiotensin-converting enzyme 2 in human heart failure: relation with myocardial function and clinical outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-011-0063-7

Plasma ACE2 activity is an independent prognostic marker in Chagas' disease and equally potent as BNP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-011-0063-7

Essential Hypertension : Part I: Definition and Etiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-011-0063-7

Genetic rat models of hypertension: relationship to human hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-011-0063-7

The role of ACE2 in cardiovascular physiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-011-0063-7

Overexpression of angiotensin-converting enzyme 2 in the rostral ventrolateral medulla causes long-term decrease in blood pressure in the spontaneously hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-011-0063-7

Brain-selective overexpression of human Angiotensin-converting enzyme type 2 attenuates neurogenic hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-011-0063-7

Genetic Ace2 deficiency accentuates vascular inflammation and atherosclerosis in the ApoE knockout mouse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-011-0063-7

Angiotensin-converting enzyme 2 attenuates atherosclerotic lesions by targeting vascular cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-011-0063-7

Angiotensin-(1-7) counterregulates angiotensin II signaling in human endothelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-011-0063-7

Angiotensin-(1-7) through receptor Mas mediates endothelial nitric oxide synthase activation via Akt-dependent pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-011-0063-7

Ablation of angiotensin (1-7) receptor Mas in C57Bl/6 mice causes endothelial dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-011-0063-7

Endothelial dysfunction and elevated blood pressure in MAS gene-deleted mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-011-0063-7

Angiotensin-(1-7) prevents activation of NADPH oxidase and renal vascular dysfunction in diabetic hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-011-0063-7

The angiotensin-(1-7) receptor agonist AVE0991 is cardioprotective in diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-011-0063-7

Improved lipid and glucose metabolism in transgenic rats with increased circulating angiotensin-(1-7).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-011-0063-7

Impairment of In Vitro and In Vivo Heart Function in Angiotensin-(1-7) Receptor Mas Knockout Mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-011-0063-7

Molecular Mechanisms Involved in the Angiotensin-(1-7)/Mas Signaling Pathway in Cardiomyocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-011-0063-7

Angiotensin-(1-7) prevents cardiomyocyte pathological remodeling through a nitric oxide/guanosine 3',5'-cyclic monophosphate-dependent pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-011-0063-7

Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the mas receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-011-0063-7

Angiotensin II-forming heart chymase is a mast-cell-specific enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-011-0063-7

Mast cell chymase limits the cardiac efficacy of Ang I-converting enzyme inhibitor therapy in rodents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-011-0063-7

Cardiac mast cell-derived renin promotes local angiotensin formation, norepinephrine release, and arrhythmias in ischemia/reperfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-011-0063-7

Evidence for a role of mast cells in the evolution to congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-011-0063-7

Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-011-0063-7

Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-011-0063-7

Enalapril attenuates downregulation of Angiotensin-converting enzyme 2 in the late phase of ventricular dysfunction in myocardial infarcted rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-011-0063-7

Telmisartan attenuates aortic hypertrophy in hypertensive rats by the modulation of ACE2 and profilin-1 expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-011-0063-7

Mineralocorticoid receptor blocker increases angiotensin-converting enzyme 2 activity in congestive heart failure patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-011-0063-7

Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-011-0063-7

Selective and specific regulation of ectodomain shedding of angiotensin-converting enzyme 2 by tumor necrosis factor alpha-converting enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-011-0063-7

Angiotensin-(1–7) Attenuates the Development of Heart Failure After Myocardial Infarction in Rats

21 January 2018

1 reference

12 December 2020

Association study of ACE2 (angiotensin I-converting enzyme 2) gene polymorphisms with coronary heart disease and myocardial infarction in a Chinese Han population

1 reference

12 December 2020

Angiotensin II-forming pathways in normal and failing human hearts

1 reference

12 December 2020

ACE2 activity is increased in monocyte-derived macrophages from prehypertensive subjects

1 reference

12 December 2020

Myocardial extra-cellular matrix and its regulation by metalloproteinases and their inhibitors

1 reference

12 December 2020

Heart disease and stroke statistics--2011 update: a report from the American Heart Association

1 reference

12 December 2020

Angiotensin-(1-7) prevents diabetes-induced cardiovascular dysfunction

1 reference

12 December 2020

Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart

1 reference

12 December 2020

Determinants of angiotensin II generation during converting enzyme inhibition

1 reference

12 December 2020

Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure

1 reference

12 December 2020

The nonpeptide angiotensin-(1-7) receptor Mas agonist AVE-0991 attenuates heart failure induced by myocardial infarction

1 reference

12 December 2020

Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1-7)

1 reference

12 December 2020

ACE2 overexpression ameliorates left ventricular remodeling and dysfunction in a rat model of myocardial infarction

1 reference

12 December 2020

Angiotensin-(1-7) prevents development of severe hypertension and end-organ damage in spontaneously hypertensive rats treated with L-NAME

1 reference

12 December 2020

Isoproterenol-induced impairment of heart function and remodeling are attenuated by the nonpeptide angiotensin-(1-7) analogue AVE 0991

1 reference

12 December 2020

10.1007/S11897-011-0063-7

Identifiers

DOI

1 reference

24 August 2017

1 reference